the aid library

Filter

3387

HEARTS technical package for cardiovascular disease management in primary health care: risk based CVD management

World Health Organization WHO (2020) C_WHO

Development of cardiovascular disease (CVD) is influenced by risk factors such as: tobacco use, an unhealthy diet, physical inactivity, obesity (which can result from a combination of unhealthy diet, physical inactivity, and other factors), elevated blood pressure (hypertension), abnormal blood l ... more

Download

View PDF

NCDs at a Glance 2025. NCDs surveillance and monitoring: Noncommunicable disease mortality and risk factor prevalence in the Americas

Pan American Health Organization PAHO (2025) C_WHO

Effective surveillance and monitoring of noncommunicable diseases (NCDs) and their risk factors are essential for informing evidence-based public health policies, addressing health inequities, and ensuring progress toward global and regional targets. By tracking trends in NCDs, their modifiable risk ... more

External Link

Clinical Profile and Management of Patient Patients with Ischemic Heart Disease and/or Peripheral Artery Disease in Clinical Practice: The APALUSA Study

Barrios, V.; Escobar, C.; Suarez C. et al. Journal of Clinical Medicine (2022) CC

This study was aimed to ascertain the clinical profile and management of patients with ischemic heart disease (IHD) and/or peripheral artery disease (PAD). In this observational and cross-sectional study developed in 80 hospitals throughout Spain, consecutive adults with stable IHD and/or PAD were i ... more

External Link

Disruption in essential health services in Mexico during COVID-19: an interrupted time series analysis of health information system data

Doubova SV, Leslie HH, Kruk ME, et al. BMJ Global Health (2021) CC

INTRODUCTION: The COVID-19 pandemic has disrupted health systems around the world. The objectives of this study are to estimate the overall effect of the pandemic on essential health service use and outcomes in Mexico, describe observed and predicted trends in services over 24 months, and to estimat ... more

Download

View PDF

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for ... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

External Link

Promoting Cardiovascular Health in the Developing World

Institute of Medicine (2010) CC

Cardiovascular disease (CVD) is often thought to be a problem of wealthy, industrialized nations. The term “cardiovascular disease” is used throughout the report to refer to cardiac disease, vascular diseases of the brain and kidney, and peripheral vascular disease. The report’s main focus is ... more

Download

View PDF

Communicable and non-communicable diseases in Africa in 2021/22

World Health Organization Africa Region; WHO Africa World Health Organization Africa Region; WHO Africa (2023) C_WHO

This report is one of the first major products of the newly established Precision Public Health Metrics unit of the UCN cluster of the WHO Regional Office for Africa. The report presents national trends in communicable and non-communicable disease burden and control in the WHO African region. It tra ... more

Ophthalmic Services Unit and the Division of Non Communicable Disease (DNCD), Ministry of Health Kenya (2017) C2

Diabète - Le nombre de personnes atteintes de diabète est passé de 108 millions en 1980 à 422 millions en 2014

World Health Organization WHO (2023) C_WHO

Le nombre de personnes atteintes de diabète est passé de 108 millions en 1980 à 422 millions en 2014

Download

View PDF

Dietary Guidelines for Indians

National Instiute for Nutrition, Indian Council for Medical Research (2011) C1

A Manual

Download

View PDF

Evaluation of the Free Diagnostics Scheme in Andhra Pradesh

Ministry of Health & Family Welfare, India World Health Organization WHO, India (2018) C_WHO

Download

View PDF

Le Diabète - Informer . Prévenir . Agir

Ethno-Medizinisches Zentrum e.V. (2013) C1

Le guide est disponible en 11 langüs: arabe, allemand, anglais, francais, italien, polonais, russe, serbe, croate, espagnol, turc. Allez voir http://www.ethno-medizinisches-zentrum.de/index.php?option=com_content&view=article&id=37&Itemid=40

Download

View PDF

Namibia: Nutrition guidelines for prevention and management of non-communicable diet related disease

Ministry of Health and Social Services (MOHSS) (2013) C1

Download

View PDF

WHO/ISH Cardiovascular Risk Prediction Charts for 14 WHO epidemiological sub-regions

World Health Organization WHO (2007) C_WHO

There are two sets of charts. One set (14 charts) can be used in settings where blood cholesterol can be measured. The other set (14 charts) is for settings in which blood cholesterol cannot be measured. Both sets are available in colour and shades of black on a compact disc. Each chart can only be ... more